Childhood Cancer

Cancer is not a single disease, but includes a variety of malignancies in which abnormal cells divide in an uncontrolled manner. These cancer cells can invade nearby tissues and can migrate by way of the blood or lymph systems to other parts of the body. The most common childhood cancers are leukemias (cancers of the white blood cells) and cancers of the brain or central nervous system, which together account for more than half of new childhood cancer cases.

Cancer in childhood is rare compared with cancer in adults, but still causes more deaths than any factor, other than injuries, among children from infancy to age 15 years. The annual incidence of childhood cancer has increased slightly over the last 30 years; however, mortality has declined significantly for many cancers due largely to improvements in treatment. Part of the increase in incidence may be explained by better diagnostic imaging or changing classification of tumors, specifically brain tumors. However, the President’s Cancer Panel recently concluded that the causes of the increased incidence of childhood cancers are not fully understood, and cannot be explained solely by the introduction of better diagnostic techniques. The Panel also concluded that genetics cannot account for this rapid change. The proportion of this increase caused by environmental factors has not yet been determined.

The causes of cancer in children are poorly understood, though in general it is thought that different forms of cancer have different causes. According to scientists at the National Cancer Institute, established risk factors for the development of childhood cancer include family history, specific genetic syndromes (such as Down syndrome), high levels of radiation, and certain pharmaceutical agents used in chemotherapy. A number of studies suggest that environmental contaminants may play a role in the development of childhood cancers. The majority of these studies have focused on pesticides and solvents, such as benzene. According to the President’s Cancer Panel, “the true burden of environmentally induced cancer has been grossly underestimated.”

The development of cancer, or carcinogenesis, is a multistep process leading to the uncontrolled growth and division of cells. This process can begin with an inherited genetic mutation or DNA damage initiated by an exogenous agent, such as exposure to a carcinogenic chemical or radiation. Additionally, many external influences, such as environmental exposures or nutrition, can alter gene expression without changing the DNA sequence. These alterations, referred to as epigenetic changes, can promote alterations in the expression of genes important for controlling cell growth and division. Because the initiation of carcinogenesis is a multistep process, multiple factors are thought to contribute to the development of cancer. Newer research suggests that childhood cancer may be caused by a combination of genetic predisposition and environmental exposure.

Different types of cancer affect children at different ages. This pattern may reflect the different types of exposures and windows of vulnerability experienced by children as they grow older, and the time between the initiation of cancer and its clinical presentation. Children can be
affected by exposures that occur during different developmental stages, such as during infancy and early childhood. Scientific evidence suggests that early childhood cancers may be related to exposure in the womb, or even to parents’ exposures prior to conception. Furthermore, recent studies suggest that susceptibility to some cancers that arise later in adulthood also may be determined while in the womb.

Leukemia is the most common form of cancer in children. According to the Centers for Disease Control and Prevention, adults and children who undergo chemotherapy and radiation therapy for cancer treatment; take immune suppressing drugs; or have certain genetic conditions, such as Down syndrome; are at a higher risk of developing acute leukemia. Multiple review articles have concluded that ionizing radiation from sources such as x-rays is associated with an increased risk of leukemia. CT scans are also an increasing source of ionizing radiation exposure to children, and may be associated with an increased risk of childhood leukemia. Further, studies have consistently shown an approximately 40% increased risk of childhood leukemia after maternal exposure to ionizing radiation during pregnancy. These confirmed risk factors, however, explain less than 10% of the incidence of childhood leukemia, meaning that the cause is unknown in at least 90% of leukemia cases.

Associations between proximity to extremely low frequency electromagnetic radiation, such as radiation from electrical power lines, and childhood leukemia have been investigated for many years. Some studies suggest an effect on cancer risk, while others do not. At this time, a variety of national and international organizations have concluded that the link between exposure to extremely low frequency electromagnetic fields and cancer is controversial or weak. Radon is a naturally occurring radioactive element that has been associated with lung cancer; some studies have also found an association between childhood leukemia and radon while other studies have not. A recent study also reported an association between naturally occurring gamma radiation and childhood leukemia.

Pesticides, solvents, hazardous air pollutants, motor vehicle exhaust, and environmental tobacco smoke have been studied for a potential role in childhood leukemia. Numerous studies have examined the link between parents’ (parental), prenatal, and childhood exposures to pesticides and childhood leukemia, and several meta-analyses of these studies have found associations between pesticide exposure and childhood leukemia in both residential and occupational settings. Recent literature has also suggested an association between childhood exposures to multiple hazardous air pollutants and leukemia. A study exploring the relationship between childhood leukemia and hazardous air pollutants (HAPs) in outdoor air found an increased risk for childhood leukemia in census tracts with the highest concentrations of a group of 25 potentially carcinogenic HAPs, including several solvents. Several other studies have found associations between leukemia and surrogate measures of exposure to motor vehicle exhaust, including residential proximity to traffic and gas stations. However, other studies conducted in California and Denmark did not find an association between these proxy measures of motor vehicle exhaust and childhood leukemia, and review studies have concluded that the overall evidence for a relationship is inconclusive.
According to the U.S. Surgeon General, there is also suggestive evidence that prenatal and postnatal exposure to environmental tobacco smoke can lead to leukemia in children.\(^5\(^9\)\)

Cancers of the nervous system, including brain tumors, are the second most common form of cancer in children. Known risk factors for childhood brain tumors include radiation therapy and certain genetic syndromes, although these factors explain only a small portion of cases.\(^6\) Some studies have also reported an association between prenatal exposure to ionizing radiation and brain tumors while a few smaller studies have not.\(^25\,^{60,\,61}\) Other research reports that head CT scans may be associated with an increased risk of brain tumors in children.\(^27\) Research also suggests that parental, prenatal, and childhood exposure to pesticides may lead to brain tumors in children.\(^43\,^{45,\,46}\) There is suggestive evidence linking prenatal and postnatal exposure to environmental tobacco smoke and childhood brain tumors, according to the U.S. Surgeon General.\(^5\(^9\)\) Many studies have examined whether there is an association between cellular phone use and brain cancer. Some of these studies have found an association between cellular phone use and some types of brain cancer, while other studies have found no association.\(^62-\,69\) Because the use of cellular phones by children has only recently become more common, no long-term epidemiological studies of cancer related to cellular phone use by children are available.\(^5\)

Lymphomas, which affect a child’s lymph system, are another common form of childhood cancer. The cause of most cases of childhood lymphoma is unknown, but it is clear that children with compromised immune systems are at a greater risk of developing lymphomas.\(^6\) Extensive review studies have found suggestive associations between parental, prenatal, and childhood exposure to pesticides and childhood lymphomas.\(^43\,^{46}\) The U.S. Surgeon General has concluded that there is also suggestive evidence linking prenatal and postnatal exposure to environmental tobacco smoke and childhood lymphomas.\(^5\(^9\)\)

Other childhood cancers that have been associated with environmental exposures include thyroid cancer, Wilms’ tumor (a type of kidney cancer), Ewing’s sarcoma (a cancer of the bone or soft tissue), and melanoma. Some research has reported an increased risk of thyroid cancer in childhood or early adulthood from exposure to ionizing radiation.\(^70-\,72\) Much of the evidence for this association comes from studies of individuals in areas with high ionizing radiation exposure due to the Chernobyl accident in eastern Europe. While the only known causal factors for Wilms’ tumor and Ewing’s sarcoma are certain birth defects and genetic conditions, there is limited research indicating that exposure to pesticides may also be a causal factor in the development of Wilms’ tumor and Ewing’s sarcoma in children.\(^36\,^{46,\,73}\) Although childhood melanoma is rare, the incidence of melanoma is increasing in children, especially in adolescents. Environmental factors associated with melanoma include sunburns, especially in childhood, and increased exposure to ultraviolet (UV) radiation.\(^74-\,76\) Depletion of the ozone layer causes more ultraviolet radiation to reach the earth’s surface. Even though the use of ozone depleting compounds has been largely phased out and the ozone layer will eventually be restored, higher levels of ultraviolet radiation reaching the earth’s surface will persist for many years to come.\(^77\,^{78}\) Finally, the increased rates of melanoma in adolescent girls and young
women may reflect increased UV exposure from sunbathing or from the widespread practice of indoor tanning.\textsuperscript{79,80}

The two indicators that follow provide the best nationally representative data available on cancer incidence and mortality among U.S. children over time. Indicator H4 presents cancer incidence and mortality for children ages 0 to 19 years for the period 1992–2009. Indicator H5 presents cancer incidence, by cancer type, for children ages 0 to 19 years for the period 1992–2006. Changes in childhood cancer mortality are most likely reflective of changes in treatment options, rather than environmental exposures. However, showing childhood cancer mortality rates in conjunction with childhood cancer incidence rates highlights the magnitude and severity of childhood cancer and indicates the proportion of children that survive.

Indicator H4 provides an indication of broad trends in childhood cancer over time, while Indicator H5 provides more detailed information about the incidence of specific types of cancer in children.
Indicator H4: Cancer incidence and mortality for children ages 0 to 19 years, 1992–2009

Indicator H5: Cancer incidence for children ages 0 to 19 years by type, 1992–2006

About the Indicators: Indicators H4 and H5 present information about the number of new childhood cancer cases and the number of deaths caused by childhood cancer. The childhood cancer case data come from a program that collects information from tumor registries located in specific geographic regions around the country each year. The childhood cancer death data come from a national database of vital statistics that collects data on numbers and causes of all deaths each year. Indicator H4 shows how the rates of all new childhood cancers and all childhood cancer deaths have changed over time, and Indicator H5 shows how the rates of specific types of childhood cancers have changed over time.

SEER

The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program has provided data on cancer incidence, survival, and prevalence since 1973. SEER obtains its cancer case data from tumor registries in various locations throughout the United States and its cancer mortality data from a national database of vital statistics that collects data on numbers and causes of all deaths each year. Each of the tumor registries collects information for all tumors within a specified geographic region. The sample population covered by the SEER tumor registries is comparable to the general U.S. population in terms of poverty and education. However, the population covered by the SEER tumor registries tends to be more urban and has a higher proportion of foreign-born persons compared with the general U.S. population.

Since its initiation in 1973, the SEER program has expanded to include a greater number of tumor registries. Currently, the SEER program includes data from 18 tumor registries, but complete data from all 18 registries are only available beginning with the year 2000. SEER data are available from 13 different tumor registries that provide data starting in 1992, and represent geographic areas containing 13.8% of the total U.S. population. The registries include the Alaska Native, Atlanta, Connecticut, Detroit, Hawaii, Iowa, Iowa, Los Angeles, New Mexico, Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and Utah tumor registries.

Data Presented in the Indicators

Childhood cancer incidence refers to the number of new childhood cancer cases reported for a specified period of time. Childhood cancer incidence is shown in Indicator H4 and Indicator H5 as the number of childhood cancer cases reported per million children for one year. The incidence rate is age-adjusted, meaning that each year’s incidence calculation uses the age distribution of children from the year 2000. For example, 25.3% of all U.S. children were between the ages of 5 and 9 years in 2000, and this percentage is assumed to be the same for...
each year from 1992 to 2009. This age adjustment ensures that differences in cancer rates over
time are not simply due to changes in the age composition of the population. Indicator H4 also
shows childhood cancer mortality as the number of deaths per million children for each year.

SEER reports the incidence data by single year of age, but reports mortality data in five age
groups for children under the age of 20: under 1 year, 1–4, 5–9, 10–14, and 15–19 years. For
this reason, both indicators use data for all children 0 to 19 years of age, in contrast to the
other indicators in this report that define children as younger than age 18 years.

Trends in the total incidence of childhood cancer, as shown by Indicator H4, are useful for
assessing the overall burden of cancer among children. However, broad trends mask changes in
the frequency of specific types of cancers that often have patterns that diverge from the overall
trend. Moreover, environmental factors may be more likely to contribute to some childhood
cancers than to others. Indicator H5 shows trends in incidence for specific types of childhood
cancers.

Some types of childhood cancers are very rare, and as such the yearly incidence is particularly
low and variable. Due to this fact, Indicator H5 shows the incidence of individual childhood
cancers in groupings of three years. Each bar in the graph represents the annual number of
cases of that specific cancer diagnosed per million children, calculated as the average number
of cases per year divided by the average population of children (in millions) per year for each
three-year period.

The SEER cancer incidence data for the 13 longer-established registries, instead of all 18, were
used to develop the H4 and H5 indicators because this allowed for more comprehensive trend
analysis while still covering a substantial portion of the population. Indicator H4 begins with the
earliest available SEER13 incidence data from 1992 and ends with 2009. Childhood cancer
mortality data for 1992 to 2009 are also used for indicator H4. Indicator H5 presents data for
the series of three-year periods beginning in 1992 and ending in 2006. In addition to the data
shown in the Indicator H4 graph, supplemental tables show childhood cancer incidence and
mortality by race/ethnicity and sex, as well as childhood cancer incidence by age group. These
data tables use data from the three most current years shown in Indicator H4, which are 2007–
2009. Combining three years of data allows for more statistically reliable estimates by
race/ethnicity, sex, and age group. Five race/ethnicity groups are used in the supplemental
tables for Indicator H4: White non-Hispanic, Black non-Hispanic, American Indian/Alaska Native
non-Hispanic, Asian or Pacific Islander non-Hispanic, and Hispanic. In addition to the data
shown in the Indicator H5 graph, a supplemental table shows childhood cancer incidence by
cancer type and age group.

Please see the Introduction to the Health section for discussion of statistical significance testing
applied to these indicators.
The age-adjusted annual incidence of cancer ranged from 153 to 161 cases per million children between 1992 and 1994 and from 172 to 175 cases per million children between 2007 and 2009. This increasing trend from 1992–2009 was statistically significant.
Childhood cancer mortality decreased from 33 deaths per million children in 1992 to 24 deaths per million children in 2009, a statistically significant decreasing trend.

Childhood cancer incidence and mortality rates were generally higher for boys than for girls. In 2007–2009, rates of cancer incidence and mortality for boys were 183 cases per million and 26 deaths per million, compared with 163 cases per million and 22 deaths per million for girls. These differences by sex were statistically significant for cancer incidence (after adjustment for age and race/ethnicity) and cancer mortality. (See Tables H4a and H4b.)

In 2007–2009, the difference in cancer incidence between boys and girls was not consistent for all races/ethnicities. No statistically significant difference in cancer incidence by sex was seen among Black non-Hispanic children or Asian or Pacific Islander non-Hispanic children. Among American Indian and Alaska Native non-Hispanic children, cancer incidence was greater for girls than for boys, although this difference was not statistically significant. Cancer incidence was greater for boys than for girls and statistically significant (after adjustment for age) among White non-Hispanic children and Hispanic children. (See Table H4a.)

In 2007–2009, childhood cancer incidence was highest among White non-Hispanic children at 188 cases per million. Hispanic children had an incidence rate of 169 cases per million, Asian and Pacific Islander non-Hispanic children had an incidence rate of 152 cases per million, American Indian and Alaska Native non-Hispanic children had an incidence rate of 137 cases per million, and Black non-Hispanic children had an incidence rate of 133 cases per million. (See Table H4a.)

The cancer incidence rate for White non-Hispanic children was statistically significantly higher than the rates of each of the other race/ethnicity categories after accounting for differences by age and sex. The cancer incidence rate for Black non-Hispanic children was also statistically significantly lower than the rates for Hispanic children and Asian and Pacific Islander non-Hispanic children after adjustment for differences by age and sex. The cancer incidence rate for Asian and Pacific Islander non-Hispanic was also statistically significantly lower than the rate for Hispanic children after adjustment for differences by age and sex. The remaining differences between race/ethnicity groups were not statistically significant.

Childhood cancer incidence rates vary by age. In 2007–2009, children under 5 and those of ages 15 to 19 years experienced the highest incidence rates of cancer at approximately 208 and 232 cases per million, respectively. Children ages 5 to 9 years and 10 to 14 years had lower incidence rates at 117 and 139 cases per million, respectively. These differences among age groups were statistically significant. (See Table H4c.)
Leukemia, which includes acute lymphoblastic leukemia and acute myeloid leukemia, was the most common cancer diagnosis for children from 2004–2006, representing 28% of total cancer cases. Incidence of acute lymphoblastic (lymphocytic) leukemia was 30 cases per million in 1992–1994 and 35 cases per million in 2004–2006. The rate of acute myeloid
(myelogenous) leukemia was 7 cases per million in 1992–1994 and 9 cases per million in 2004–2006.

- The increasing trend for incidence of acute lymphoblastic leukemia was statistically significant after accounting for differences by age, sex, and race/ethnicity. The trend for acute myeloid leukemia was not statistically significant.


- Lymphomas, which include Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and Burkitt’s lymphoma, represented 14% of childhood cancers in 2004–2006. Incidence of Hodgkin’s lymphoma was 12 cases per million in 1992–1994 and 11 per million in 2004–2006. There were approximately 7 cases of non-Hodgkin’s lymphoma per million children in 1992–1994 and 9 per million in 2004–2006. Incidence of Burkitt’s lymphoma remained constant from 1992–2006 (2 cases per million children). The increasing trend in the incidence rate of non-Hodgkin’s lymphoma was statistically significant, while there was no statistically significant trend in the incidence rate of Hodgkin’s lymphoma or Burkitt’s lymphoma.

- Between the years 1992 and 2006, increasing trends in the incidence of soft tissue sarcomas, malignant melanomas, and hepatoblastomas were statistically significant, as was the decreasing trend in the incidence of Wilms’ tumor (tumors of the kidney). There was no statistically significant trend in the incidence rate of thyroid carcinomas, other and unspecified carcinomas, germ cell tumors, osteosarcomas, Ewing’s sarcomas, or neuroblastomas.

- The increasing trend in the incidence rate of hepatoblastomas was statistically significant after accounting for differences by age, sex, and race/ethnicity.

- Different types of cancer affect children at different ages. The incidence of neuroblastomas and Wilms’ tumor (tumors of the kidney) was highest for young children (ages 0 to 4 years). Leukemias occur in all age groups, but the incidence is highest among 0- to 4-year-olds. The incidence of Hodgkin’s and non-Hodgkin’s lymphomas, thyroid carcinomas, malignant melanomas, other and unspecified carcinomas, germ cell tumors, and osteosarcomas was higher in those 15 to 19 years old. Differences among age groups were statistically significant for each of these cancer types. (See Table H5a.)
References | Health

Health

Childhood Cancer
Childhood Cancer (continued)


References | Health

**Childhood Cancer (continued)**


**Childhood Cancer (continued)**


Health

Childhood Cancer

Table H4: Cancer incidence and mortality for children ages 0 to 19 years, 1992-2009

<table>
<thead>
<tr>
<th>1992-1997</th>
<th>Age-adjusted rate per million children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>158.4</td>
</tr>
<tr>
<td>Mortality</td>
<td>33.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1998-2003</th>
<th>Age-adjusted rate per million children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1998</td>
</tr>
<tr>
<td>Incidence</td>
<td>164.1</td>
</tr>
<tr>
<td>Mortality</td>
<td>27.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2004-2009</th>
<th>Age-adjusted rate per million children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2004</td>
</tr>
<tr>
<td>Incidence</td>
<td>167.2</td>
</tr>
<tr>
<td>Mortality</td>
<td>27.2</td>
</tr>
</tbody>
</table>

DATA: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program

Table H4a: Cancer incidence for children ages 0 to 19 years by race/ethnicity and sex, 2007-2009

<table>
<thead>
<tr>
<th>Age-adjusted rate per million children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>All Races/Ethnicities (n=5,974)</td>
</tr>
<tr>
<td>White non-Hispanic (n=2,963)</td>
</tr>
<tr>
<td>Black non-Hispanic (n=574)</td>
</tr>
<tr>
<td>American Indian/Alaska Native non-Hispanic (n=69)</td>
</tr>
<tr>
<td>Asian or Pacific Islander non-Hispanic (n=560)</td>
</tr>
<tr>
<td>Hispanic (n=1,717)</td>
</tr>
</tbody>
</table>

DATA: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program

Table H4b: Cancer mortality for children ages 0 to 19 years by race/ethnicity and sex, 2007-2009

<table>
<thead>
<tr>
<th>Age-adjusted rate per million children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>All Races/Ethnicities (n=6,071)</td>
</tr>
<tr>
<td>White non-Hispanic (n=3,384)</td>
</tr>
<tr>
<td>Black non-Hispanic (n=900)</td>
</tr>
<tr>
<td>American Indian/Alaska Native non-Hispanic (n=55)</td>
</tr>
<tr>
<td>Asian or Pacific Islander non-Hispanic (n=248)</td>
</tr>
<tr>
<td>Hispanic (n=1,386)</td>
</tr>
</tbody>
</table>

DATA: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program

Following the recommendations of the National Cancer Institute, the mortality rates for all the groups except for “All races/ethnicities” excluded data from the following states, which had large numbers with unknown ethnicity: North Dakota and South Carolina. See http://seer.cancer.gov/seerstat/variables/mort/origin_recode_1990+/index.html.
Table H4c: Cancer incidence for children 0 to 19 years by age, 2007-2009

<table>
<thead>
<tr>
<th>Age</th>
<th>Age-adjusted rate per million children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages 0 to 4 years</td>
<td>207.6</td>
</tr>
<tr>
<td>Ages 5 to 9 years</td>
<td>116.9</td>
</tr>
<tr>
<td>Ages 10 to 14 years</td>
<td>139.0</td>
</tr>
<tr>
<td>Ages 15 to 19 years</td>
<td>232.3</td>
</tr>
<tr>
<td>Ages 0 to 19 years</td>
<td>173.4</td>
</tr>
</tbody>
</table>

DATA: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program

Table H5: Cancer incidence for children ages 0 to 19 years, by type, 1992-2006

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute lymphoblastic leukemia</td>
<td>29.5</td>
<td>32.3</td>
<td>33.4</td>
<td>32.4</td>
<td>34.5</td>
</tr>
<tr>
<td>Central nervous system tumors</td>
<td>28.7</td>
<td>26.8</td>
<td>26.9</td>
<td>29.6</td>
<td>27.0</td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>11.3</td>
<td>11.5</td>
<td>10.8</td>
<td>12.0</td>
<td>12.6</td>
</tr>
<tr>
<td>Soft tissue sarcomas</td>
<td>10.2</td>
<td>11.5</td>
<td>12.0</td>
<td>11.5</td>
<td>12.3</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>12.3</td>
<td>11.6</td>
<td>12.2</td>
<td>11.2</td>
<td>10.8</td>
</tr>
<tr>
<td>Acute myeloid leukemia</td>
<td>7.3</td>
<td>7.7</td>
<td>8.3</td>
<td>8.0</td>
<td>8.5</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>7.4</td>
<td>7.2</td>
<td>7.7</td>
<td>9.0</td>
<td>8.8</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>7.4</td>
<td>7.7</td>
<td>6.9</td>
<td>7.3</td>
<td>8.0</td>
</tr>
<tr>
<td>Malignant melanoma</td>
<td>4.4</td>
<td>4.7</td>
<td>4.7</td>
<td>5.8</td>
<td>5.7</td>
</tr>
<tr>
<td>Thyroid carcinoma</td>
<td>5.2</td>
<td>5.2</td>
<td>6.2</td>
<td>6.1</td>
<td>5.5</td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td>4.9</td>
<td>4.8</td>
<td>4.8</td>
<td>5.3</td>
<td>4.5</td>
</tr>
<tr>
<td>Wilms’ tumor</td>
<td>5.7</td>
<td>5.8</td>
<td>5.5</td>
<td>4.7</td>
<td>4.4</td>
</tr>
<tr>
<td>Other and unspecified carcinomas†</td>
<td>3.8</td>
<td>3.9</td>
<td>3.9</td>
<td>3.6</td>
<td>3.3</td>
</tr>
<tr>
<td>Ewing’s sarcoma</td>
<td>3.2</td>
<td>2.3</td>
<td>2.2</td>
<td>2.5</td>
<td>2.8</td>
</tr>
<tr>
<td>Burkitt’s lymphoma</td>
<td>2.0</td>
<td>1.9</td>
<td>2.3</td>
<td>2.4</td>
<td>2.2</td>
</tr>
<tr>
<td>Hepatoblastoma</td>
<td>1.1</td>
<td>1.2</td>
<td>1.8</td>
<td>1.5</td>
<td>1.7</td>
</tr>
</tbody>
</table>

DATA: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program

† “Other and unspecified carcinomas” represents all carcinomas and other malignant epithelial neoplasms other than thyroid carcinoma and malignant melanoma.
### Table H5a: Cancer incidence rates per million children for malignant cancers by age and type, 2004-2006

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Age-adjusted rate per million children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ages 0 to 4 years</td>
</tr>
<tr>
<td>Acute lymphoblastic leukemia</td>
<td>66.3</td>
</tr>
<tr>
<td>Central nervous system tumors</td>
<td>35.1</td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>7.5</td>
</tr>
<tr>
<td>Soft-tissue sarcomas</td>
<td>11.1</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>NA**</td>
</tr>
<tr>
<td>Acute myeloid leukemia</td>
<td>13.2</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>3.2</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>28.5</td>
</tr>
<tr>
<td>Malignant melanoma</td>
<td>0.9*</td>
</tr>
<tr>
<td>Thyroid carcinoma</td>
<td>NA**</td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td>NA**</td>
</tr>
<tr>
<td>Wilms’ tumor</td>
<td>13.4</td>
</tr>
<tr>
<td>Other and unspecified carcinomas†</td>
<td>NA**</td>
</tr>
<tr>
<td>Ewing’s sarcoma</td>
<td>NA**</td>
</tr>
<tr>
<td>Burkitt’s lymphoma</td>
<td>1.5</td>
</tr>
<tr>
<td>Hepatoblastoma</td>
<td>6.9</td>
</tr>
</tbody>
</table>

DATA: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program

† “Other and unspecified carcinomas” represents all carcinomas and other malignant epithelial neoplasms other than thyroid carcinoma and malignant melanoma.

* The estimate should be interpreted with caution because the standard error of the estimate is relatively large: the relative standard error, RSE, is at least 30% but is less than 40% (RSE = standard error divided by the estimate).

** Not available. The estimate is not reported because it has large uncertainty: the relative standard error, RSE, is 40% or greater (RSE = standard error divided by the estimate).